徐晓莉，女，博士，药物化学专业副教授，博士生导师。
2009年7月本科毕业于中国药科大学国家生命科学与技术人才培养基地班，后继续攻读中国药科大学药学院药物化学专业硕博连读研究生，2014年6月获理学博士学位，2014年7月-2017年6月在中国药科大学中药学院从事师资博士后研究，2017年7月获得副高级职称并留校任教于药学院药物化学系。
主要研究方向为药物化学，通过运用计算机辅助药物设计、化学生物学、药物化学等多学科交叉手段，基于针对蛋白伴侣系统及肿瘤免疫系统开展创新药物研发工作。
以第一作者和通讯作者在学科权威杂志Journal of Medicinal Chemistry，European Journal of Medicinal Chemistry等发表论文15篇。作为课题负责人主持了国家自然科学基金面上项目二项，青年基金项目一项，江苏省自然科学基金青年基金一项，中央高校基本科研业务费重点项目一项。2019年荣获第二十二届中国药学会-施维雅青年药物化学奖，并获得中国药科大学“岛津青年****”等荣誉
联系方式
Email: xuxiao_li@126.com
Phone：**
代表性论文：
[1]. LeiWang, JingshengJiang, LixiaoZhang, QiuyueZhang, JianruiZhou,Li Li, Xiao-li Xu,*Qidong You*.Discovery and Optimization of Small Molecules Targeting theProtein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer J. Med. Chem. 2020 63 (3), 1281-1297.
[2]. Han Zhang，Qi-Dong You*，Xiao-Li Xu* Targeting Stimulator of Interferon Genes (STING):
A Medicinal Chemistry Perspective J. Med. Chem.2020, 63 (8):3785-3816
[3]. Li Li, Lei Wang, Qi-Dong You,* and Xiao-Li Xu*Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. J. Med. Chem.2020, 63, 5, 1798-1822. IF: 6.023.
[4]. Fen Jiang, An-ping Guo, Jia-chen Xu, Qi-Dong You,*Xiao-Li Xu*Discovery of a Potent Grp94 Selective Inhibitor with Anti- Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis. J. Med. Chem.2018, 61, 9513?9533.
[5]. Fen Jiang, Hui-Jie Wang, Yu-Hui Jin, Qiong Zhang, Zhi-Hui Wang, Jian-Min Jia,Fang Liu, Lei Wang,Qi-Chao Bao, Dong-Dong Li, Qi-Dong You,*and Xiao-Li Xu*.Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90. J. Med. Chem. 2016,59, 10498-10519.
[6].Wang, L.₁; Xu, X.₁; Jiang, Z.*; You, Q.*, Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery. 2020. Acta Pharm Sin B. 2020, in press.
[7].Xiao-li Xu, Ying-rui Yang, Xiao-fei Mo, Jin-lian Wei, Xiao-jin Zhang, You, Q. D* Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1a pathway. Eur. J. Med. Chem., 2017, 137, 45-62.
[8].Wang, L,Li, L.,Zhou, Z. H.,Jiang, Z. Y.,You, Q. D*., Xiao-Li Xu*.Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction. Eur. J. Med. Chem., 2017, 136, 63-73.
[9].Fen Jiang, An-ping Guo, Jia-cheng Xu, Hui-Jie Wang, Xiao-fei Mo, You, Q.-D.*,Xiao-Li Xu*. Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors. Eur. J. Med. Chem., 2017, 141, 1-14.